Elizabeth Urrea, APRN
Gerontology · Tulsa, OKNPI 1033802236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $772, 6.8 times the $114 reported in 2023.
Across 82 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$356
- Novo Nordisk$284
- AstraZeneca$122
- Dexcom, Inc.$116
- Otsuka America Pharmaceutical, Inc.$100
- Lilly USA, LLC$83
- plus $478 from 12 others
What the payments were for
- Food & beverage$1,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $356 |
| Novo Nordisk | 16 | $284 |
| AstraZeneca | 7 | $122 |
| Dexcom, Inc. | 5 | $116 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Lilly USA, LLC | 5 | $83 |
| Exact Sciences | 5 | $82 |
| UCB, Inc. | 2 | $76 |
| Bayer | 5 | $75 |
| Pfizer | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Astellas Pharma US Inc | 1 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Amgen | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$1,540 in reported general payments places this provider in the 60th percentile of 73 gerontology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $73,256 |
| RexultiBrexpiprazole | 63 | $44,681 |
| OzempicSemaglutide | 31 | $44,661 |
| FarxigaDapagliflozin Propanediol | 33 | $17,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,800 |
| JardianceEmpagliflozin | 55 | $16,769 |
| VraylarCariprazine Hcl | 11 | $7,872 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $6,689 |
| Budesonide | 27 | $5,827 |
| Celecoxib | 101 | $5,160 |
| Megestrol Acetate | 18 | $4,460 |
| NovologInsulin Aspart | 44 | $3,651 |
| Mirtazapine | 102 | $3,621 |
| JanuviaSitagliptin Phosphate | 12 | $3,432 |
| Memantine Hcl | 55 | $3,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $50 | $73,256170 claims |
| Novo NordiskOzempic, Novolog | $284 | $48,31275 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $100 | $44,68163 claims |
| AstraZenecaFarxiga | $122 | $17,51433 claims |
| Boehringer IngelheimJardiance | $16 | $16,76955 claims |
| AbbVieVraylar | $356 | $7,87211 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $1,16374 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 73 gerontology providers in Oklahoma.
Other gerontology in Tulsa
- Shelley TriplettTulsa$7K
- Kjerista TiptonTulsa$6K
- Bailey StremmeTulsa$5K
- Andrea ByfordTulsa$4K
- Samira QueenTulsa$3K
- Christina LansdowneTulsa$3K
- Heidi CookTulsa$2K
- Lori OrmsbyTulsa$1K
- Nina HayesTulsa$1K
- Veronica ManoilaTulsa$958
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.